Retrial of selective serotonin reuptake inhibitors in children with pervasive developmental disorders: A retrospective chart review

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 111-117

  Henry, Charles A ^a,d   Shervin, David ^a   Neumeyer, Ann ^a   Steingard, Ronald ^b   Spybrook, Jessaca ^c   Choueiri, Roula ^a   Bauman, Margaret ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c WESTERN MICHIGAN UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LORAZEPAM; MEMANTINE; PAROXETINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROATE SEMISODIUM;

AGGRESSION; AGITATION; ARTICLE; ASPERGER SYNDROME; AUTISM; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DISTRACTIBILITY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INDIGESTION; INSOMNIA; MALE; MEDICAL RECORD REVIEW; SIDE EFFECT; STEREOTYPY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 65249094245     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.037     Document Type: Article

References (42)

1. Alcami Pertejo M, Peral Guerra M, Gilaberte I: [Open study of fluoxetine in children with autism]. Actas Espanolas de Psiquiatria 28:353-356, 2000.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, D.C., American Psychiatric Association, 1994.
3. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG: Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 44:1309-1312, 1994.
4. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, DeBar L, McCracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA 299:901-913, 2008.
5. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH: Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. J Child Adolesc Psychopharmacol 7:109-121, 1997.
6. Brown WA, Harrison W: Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 56:30-34, 1995.
7. Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C, Cartwright C, Mosovich S: Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: A pilot study. Int J Neuropsychopharmacol 4:119-125, 2001.
8. Calabrese JR, Londborg PD, Shelton MD, Thase ME: Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 64:562-567, 2003.
9. Damore J, Stine J, Brody L: Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry 37:248-249, 1998.
10. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S: A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87:141-145, 1993.
11. DeLong GR, Teague LA, McSwain Kamran M: Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 40:551-562, 1998.
12. DeLong GR, Ritch CR, Burch S: Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44:652-659, 2002.
13. Fukuda T, Sugie H, Ito M, Sugie Y: [Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder]. No to Hattatsu [Brain & Development] 33:314-318, 2001.
14. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB: Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry 149:363-366, 1992.
15. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447, 1993.
16. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P: Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 57:333-336, 1996.
17. Henry CA, Steingard R, Venter J, Guptill J, Halpern EF, Bauman M: Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: A chart review. J Child Adolesc Psychopharmacol 16:187-195, 2006.
18. Hollander E, Kaplan A, Cartwright C, Reichman D: Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. J Child Neurol 15:132-135, 2000.
19. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R: A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582-589, 2005.
20. Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E: Divalproex sodium vs. placebo in the treat- ment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 9:209-213, 2006.
21. Joffe RT, Levitt AJ, Sokolov ST, Young LT: Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 57:114-115, 1996.
22. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ: Clomipramine in autism: Preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 31:746-750, 1992.
23. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996.
24. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH: Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J Clin Psychopharmacol 18:62-66, 1998.
25. McDougle CJ, Kresch LE, Posey DJ: Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30:427-435, 2000.
26. McDougle CJ, Posey D: Genetics of childhood disorders: XLIV. Autism, Part 3: Psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry 41:1380-1383, 2002.
27. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B: Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psycho-pharmacology. Am J Psychiatry 162:1142-1148, 2005.
28. Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC: Use of citalopram in pervasive developmental disorders. J Develop Behav Pediat 24:104-108, 2003.
29. National Institute of Mental Health: Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology search. Psychopharmacol Bull 21:839-843, 1985.
30. Nierenberg AA, Katz J, Fava M: A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 30:13-29, 2007.
31. Owley T, Walton L, Salt J, Guter SJ, Jr., Winnega M, Leventhal BL, Cook EH, Jr.: An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44:343-348, 2005.
32. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242, 2006.
33. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP: Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7:9-15, 1997.
34. Sugie Y, Sugie H, Fukuda T, Ito M, Ohzeki T: [Studies on the adverse effects of fluvoxamine treatment in children with autistic disorder: Correlation with genetic polymorphism in serotonin related genes]. No to Hattatsu [Brain & Development]. 35:233-237, 2003.
35. Tanguay PE: Pervasive developmental disorders: A 10-year review. J Am Acad Child Adolesc Psychiatry 39:1079-1095, 2000.
36. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG: Fluoxetine treatment of patients with major depressive dis- order who failed initial treatment with sertraline. J Clin Psychiatry 58:16-21, 1997.
37. Thase ME, Feighner JP, Lydiard RB: Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry 62:683-687, 2001.
38. Thase ME, Ferguson JM, Lydiard RB, Wilcox CS: Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 16:128-133, 2002.
39. Volkmar F, Cook EH, Jr., Pomeroy J, Realmuto G, Tanguay P: Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 38:32S-54S, 1999.
40. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004.
41. Williams JW Jr, Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J: A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132:743-756, 2000.
42. Wozniak J, Biederman J, Faraone SV, Frazier J, Kim J, Millstein R, Gershon J, Thornell A, Cha K, Snyder JB: Mania in children with pervasive developmental disorder revisited. J Am Acad Child Adolesc Psychiatry 36:1552-1559; discussion 1559-1560, 1997.